10-K: Anebulo Pharmaceuticals Prioritizes Intravenous Selonabant for Pediatric Cannabis Toxicity Treatment

Anebulo Pharmaceuticals shifts focus to an intravenous formulation of selonabant for pediatric cannabis poisoning, citing faster approval potential and a critical unmet need.

Summary

• Anebulo Pharmaceuticals is a clinical-stage biotech company developing treatments for cannabis toxicity.
• Their lead product, selonabant, is intended to reverse the negative effects of cannabis poisoning and intoxication.
• The company is prioritizing an intravenous (IV) formulation of selonabant for pediatric patients with unintentional cannabis poisoning.
• This decision is based on the potential for faster regulatory approval and the significant unmet medical need in children.
• Anebulo has received a $1.9 million grant from the National Institute on Drug Abuse (NIDA) to support the development of intravenous selonabant.
• The company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.
• The company believes that the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval for intravenous treatment of unintentional cannabis poisoning in the pediatric population.
• The company has completed a Phase 2 trial in the Netherlands, which showed positive results for oral selonabant in treating adults with ACI.
• The company believes that the number of cannabis-related emergency department visits grew to approximately 1.8 million patients in 2021.
• The company has two issued US patents and rights to six additional patent applications, two pending Patent Cooperation Treaty (PCT) applications and additional international patent applications, covering various methods of use of the compound, aspects of selonabant, and delivery systems.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments like the NIDA grant and progress in clinical trials, the company's lack of revenue, accumulated deficit, and need for future capital raises raise concerns. The shift in focus to pediatric treatment is a strategic move, but it also introduces new uncertainties.

Positives

• The company has developed a suitable IV formulation of selonabant for use in the pediatric population.
• The company has received a $1.9 million grant from NIDA to support the development of intravenous selonabant.
• The company has completed a Phase 2 trial in the Netherlands, which showed positive results for oral selonabant in treating adults with ACI.
• The company believes that the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval for intravenous treatment of unintentional cannabis poisoning in the pediatric population.

Negatives

• The company has not generated any revenue since its inception.
• The company has an accumulated deficit of $65.4 million.
• The company will need to raise additional capital in the future, which may be unavailable.
• The debt facility may be secured by substantially all of the company's assets and a default thereunder would have material adverse consequences on the company's financial condition, operating results, and business.

Risks

• The company has not generated any revenue since its inception and may never become profitable.
• The company will need to raise additional capital in the future, which may be unavailable to it.
• The debt facility may be secured by substantially all of the company's assets and a default thereunder would have material adverse consequences on the company's financial condition, operating results, and business.
• The company has limited operating history as a publicly traded company.
• The company's current and future operations substantially depend on its Founder and Chief Executive Officer.
• Adverse developments affecting the financial services industry could adversely affect the company's business.
• If the company is unable to obtain and maintain sufficient patent protection for selonabant, its ability to successfully commercialize its current or future product candidates may be adversely affected.
• If the company fails to comply with its obligations under its current or future intellectual property license agreements or experience disruptions with its current or future licensors, it could lose intellectual property rights.
• The company may not be able to protect its intellectual property rights throughout the world.
• The expiration or loss of patent protection may adversely affect the company's future revenues and operating earnings.
• Delays in clinical trials for selonabant, its lead drug candidate, could adversely affect the company's business.
• If the company is not able to obtain regulatory approvals for selonabant, it will not be able to commercialize it.
• Even if the company receives regulatory approval for selonabant, it may not be able to successfully commercialize the product and the revenue that it generates from its sales, if any, may be limited.
• Interim and preliminary data from the company's preclinical studies or clinical trials are subject to audit and verification procedures that could result in material changes in the final data.
• Even if the company obtains marketing approval for selonabant, it will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense.
• Any products the company develops may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming the company's business.
• Legislation may make it difficult for the company to commercialize selonabant and affect the prices it may obtain.
• The company's lead drug candidate, selonabant, may face competition sooner than expected.
• Any delays in the necessary studies of selonabant could result in increased costs to the company.
• Clinical drug development involves a lengthy and expensive process with an uncertain outcome.
• The company may be exposed to product liability risks, and clinical and preclinical liability risks.
• The company's lead product candidate, selonabant, may have undesirable side effects.
• If the company is unable to establish its own marketing and sales capabilities, or enter into agreements with third parties to market and sell its products after approval, it may not be able to generate product revenues.
• The development of new drugs could impair the company's ability to grow its business and remain competitive.
• The company's dependance on third parties for its preclinical testing and clinical trials may result in costs and delays that prevent it from obtaining regulatory approval or successfully commercializing product candidates.
• Third parties the company will rely upon to manufacture selonabant may fail to obtain government approvals, provide the company with sufficient quantities or qualities or do so at acceptable prices, which may affect commercialization.
• The company's reliance on collaborations with third parties to develop and commercialize selonabant is subject to inherent risks and may result in delays in product development and lost or reduced revenues.
• Legislative or regulatory reform of the healthcare system may affect the company's ability to sell its products profitably.
• Clinical trials for selonabant have and may in the future be conducted outside the United States and not under an IND, and where this is the case, the FDA may not accept data from such trials.
• The trading price and volume of the company's common stock has been and may continue to be volatile.
• Future sales of a substantial number of the company's shares of common stock could depress the trading price.
• The company's principal stockholders are able to exert significant control over matters subject to stockholder approval.
• Anti-takeover provisions in the company's charter documents could discourage, delay or prevent a change in control.
• The company's charter provides that the Delaware Chancery Court is the exclusive forum for substantially all disputes between the company and its stockholders, and federal district courts is the exclusive forum for Securities Act claims.
• The company does not expect to pay any dividends on its common stock.
• The company is required to establish and maintain effective internal control over financial reporting.
• The company has increased costs as a public company and its management is required to devote time to compliance.
• Changes in accounting principles or guidance could result in unfavorable accounting charges or effects.
• Reduced disclosure requirements for emerging growth companies, may make the company's securities less attractive.
• Changes in tax laws or regulations may have a material adverse effect on the company's business.
• The company's ability to use net operating loss carryforwards and certain other tax attributes may be limited.
• If analysts do not publish favorable reports about the company, its stock price and trading volume could decline.
• Health epidemics or pandemics may adversely affect the company's financial condition and results of operations.
• Unstable market and economic conditions, geopolitical conditions, and other factors beyond the company's control may have serious adverse consequences on the company's business, financial condition and stock price.
• Inflation may adversely affect the company by increasing its costs.
• The company's actual or perceived failure to comply with policies and other obligations related to data privacy and security could lead to regulatory investigations or actions and other adverse business consequences.
• If the company's internal information technology systems or sensitive information, or those of its third-party contractors or consultants, are or were compromised, it could experience adverse consequences.
• The company cannot assure you that its common stock will remain listed on the Nasdaq Capital Market.

Future Outlook

The company expects to continue incurring significant operating losses and negative cash flows from operations in the future as it funds its operating losses and capital expenditures. The company anticipates that its cash and cash equivalents, plus available funding under the Loan and Security Agreement (LSA), will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance date of the financial statements. The company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.

Management Comments

• The recent decision by the United States Department of Justice to support the rescheduling of marijuana from a schedule I to a schedule III-controlled substance is a move that we believe will ultimately lead to increased use of cannabis-containing products among US households.
• We have evaluated the potential advantages of prioritizing a near-term solution for children with more serious symptoms over progressing our plans for clinical studies to support an adult oral ACI treatment and have decided to focus current efforts on the pediatric indication at this time.
• Our belief is that the path to approval for an oral treatment for adult ACI may be facilitated by an initial approval for intravenous treatment of unintentional cannabis poisoning in the pediatric population.

Industry Context

The document highlights the increasing prevalence of cannabis toxicity, particularly in states with legalized cannabis, and the lack of approved treatments, positioning Anebulo as a potential leader in this space. The shift towards prioritizing pediatric treatment reflects a growing awareness of the unique risks faced by children.

Comparison to Industry Standards

• Aelis Farma is developing a medication based on a pregnenolone derivative to treat cannabis use disorders in collaboration with Indivior PLC, which is a competitor in the cannabis treatment space.
• Opiant Pharmaceuticals, Inc. (acquired by Indivior PLC in March 2023), which is developing a drinabant injection to treat acute cannabis overdose, is also a competitor in the cannabis treatment space.
• The company is relying on studies performed by a third party for a different indication, obesity, and the FDA or a foreign equivalent regulator may disagree with the company's ability to reference the clinical data generated by such third-party trials in connection with the indication for cannabis toxicity and addiction.

Management Changes

Related Party Transactions

• The company leases office space from JFL Capital Management LLC, a company controlled by Joseph F. Lawler, a director of the company.
• The company entered into a Loan and Security Agreement with 22NW, LP and JFL Capital Management LLC, where Joseph F. Lawler is the Managing Member of JFL and Aron R. English is the President and Portfolio Manager of 22NW, and both are directors of the company.

Stakeholder Impact

• Shareholders may experience dilution due to potential future equity offerings and the issuance of shares under the LSA.
• Employees may be affected by potential changes in the company's strategy and financial condition.
• Patients may benefit from the development of new treatments for cannabis toxicity.
• Creditors may be impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company aims to complete IND-enabling activities and the scale up of its formulation of intravenous selonabant around calendar year end 2024.
• The company expects to enroll the first healthy adult volunteer in the first half of calendar 2025.
• The company plans to pursue the adult ACI market opportunity once it is able to provide a necessary treatment for pediatric patients.

Key Dates

Keywords

selonabant, cannabis toxicity, acute cannabinoid intoxication, pediatric cannabis poisoning, intravenous formulation, NIDA grant, clinical trials, CB1 antagonist, emergency department visits, THC